Results

Total Results: 2,208 records

Showing results for "drug".

1741. CARDIOVASCULAR (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/cardiovascular-horizon-scan-high-impact-1412.pdf
      December 01, 2014 - The drawbacks include nonhemorrhagic side effects, potential drug-drug interactions, and the fact that … warfarin, these therapies have other drawbacks, including nonhemorrhagic side effects, potential for drug-drug … Food and Drug Administration (FDA). … Drug coverage guidelines: Juxtapid. [internet]. … Food and Drug Administration (FDA).

1742. #05 DEPRESSION (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1412.pdf
      December 01, 2014 - Drug Enforcement Administration classifies ketamine as a Schedule III drug, requiring a license and … Drug Enforcement Administration. … Research suggests new drug targets for depression. … Washington (DC): Drug Enforcement Administration, U.S. … Food and Drug Administration (FDA) [accessed 2013 Aug 19]. [2 p].

1743. Antipsychotics-Adults Executive (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/antipsychotics-adults_executive.pdf
      August 01, 2012 - Food and Drug Administration (FDA). … contrast to previous reviews, this CER focuses on comparisons of individual medications rather than drug … • Drug dosage. • Followup period. … National Library of Medicine’s TOXLINE® and the MedEffect™ Canada Adverse Drug Reaction Database. … In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.

1744. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/dementia-horizon-scan-high-impact-1412.pdf
      February 01, 2015 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … Food and Drug Administration (FDA) for antidepressant use. … Food and Drug Administration (FDA) treat only AD symptoms; they are not disease-modifying. … -based online aggregator of prescription-drug prices found prices between $25 and $250 for a single … Some of the experts believe that as a potentially affordable, easily administered drug, intranasal

1745. For persons who present with acute cough illness (ACI), what is the comparative effectiveness of various interventions for reducing inappropriate antimicrobial use? | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/get-involved/nominated-topics/for-persons-who-present-with-acute-cough-illness-aci-what-is-the-comparative-effectiveness-of-various-interventions-for-reducing-inappropriate-antimicrobial-use
      November 01, 2017 - unnecessary antibiotic prescribing which will in turn reduce costs, time to return to work, adverse drug … Drug resistance, development of serious complications, mortality from any cause, side effects due to … of hospital stay Appropriateness for EHC Program Does your question include a health care drug

1746. Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/antipsychotics-children-future_research.pdf
      February 01, 2012 - Food and Drug Administration, Division of Psychiatry Products Silver Spring, MD Laurence Greenhill … Food and Drug Administration-approved second-generation antipsychotics Generic Name Indications Age … Finding a drug-placebo difference equivalent to the minimum difference between drug and no treatment … Even if a between-drug difference were equivalent to the maximum between-drug difference in the study … Pharmacoepidemiol Drug Saf 2010 May;19(5):429-35. PMID: 20306454. 5.

1747. For patients with Crohn's disease, what treatments or therapies, alone or in conjunction with one another, provide the highest rate of disease management with the lowest risk of long term complications, particularly in young women? | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/get-involved/nominated-topics/for-patients-with-crohns-disease-what-treatments-or-therapies-alone-or-in-conjunction-with-one-another-provide-the-highest-rate-of-disease-management-with-the-lowest-risk-of-long-term-complications-particularly-in-young-wome
      November 01, 2017 - Appropriateness for EHC Program Does your question include a health care drug, intervention, device

1748. Dietary Supplements | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/health-topics/dietary-supplements
      July 25, 2017 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

1749. #05 DEPRESSION (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1512.pdf
      December 01, 2015 - Drug Enforcement Administration, which classifies it as a Schedule III drug requiring a license and … Drug Enforcement Administration license.39,40 High-dose ketamine can be abused as a street drug known … Biopharm Drug Dispos. 2003 Jan;24(1):37-43. … Drug Enforcement Administration. … Research suggests new drug targets for depression.

1750. Observed Association Between Antidepressant Use and Pneumonia Risk Was Confounded by Comorbidity Measures (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/antidepressants-seniors-pneumonia_research.pdf
      May 01, 2008 - implicated as risk factors for pneumonia, including chronic neurologic and pulmonary conditions [4]), drug … to 1.99) 10 * Adjusted for age, sex, calendar year, and current use of an antidepressant drug … to 7.85) 12 * Adjusted for age, sex, calendar year, and current use of an antidepressant drug

1751. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/diabetic-neuropathy-disposition-170707.pdf
      March 24, 2017 - itself: Coffey et al, Mortality associated with implantation and management of intrathecal opioid drug … We are no longer analyzing anticonvulsants together as a drug class, but are only analyzing comparison … If the more modern studies on pregabalin are mostly negative, why would you conclude that this drug … WITH GABAPENITIN ALTHOUGH THERE ARE A LOT OF REPORTED PATIENT SIDE EFFECTS WITH DULOXETINE , the drug … For head to head trials, we have now taken out evaluations of anticonvulsants as a drug class since

1752. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/diabetic-neuropathy-disposition-170707.pdf
      March 24, 2017 - itself: Coffey et al, Mortality associated with implantation and management of intrathecal opioid drug … We are no longer analyzing anticonvulsants together as a drug class, but are only analyzing comparison … If the more modern studies on pregabalin are mostly negative, why would you conclude that this drug … WITH GABAPENITIN ALTHOUGH THERE ARE A LOT OF REPORTED PATIENT SIDE EFFECTS WITH DULOXETINE , the drug … For head to head trials, we have now taken out evaluations of anticonvulsants as a drug class since

1753. Layout 1 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/antidepressants-update_executive.pdf
      December 01, 2011 - (i.e., continuation phase) or recurrence (i.e., maintenance phase) when a patient: • continues the drug … indications (major depressive disorder, dysthymia, minor depression, subsyndromal depressive disorder), drug … We assessed statistically each of the 78 possible drug comparisons of second-generation antidepressants … full-text articles excluded: 7 Foreign languages 10 Too short of duration 84 Wrong population 142 Wrong drug … meta-analyses on the response to treatment (at least 50 percent improvement from baseline) for six drug–drug

1754. Template for Reports Developed (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/allergy-seasonal_research-protocol.pdf
      March 08, 2012 - Food and Drug Administration (FDA) for the treatment of SAR. … Drug class review: nasal corticosteroids: final report update 1. … Drug class review: newer antihistamines: final report update 2. … Food and Drug AdministrationCenter for Drug Evaluation and Research. … Food and Drug Administration; April 2000.

1755. Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/survival-quality/research
      November 01, 2017 - In comparison to overall survival (OS), the gold standard for cancer drug evaluation, PFS can be evaluated … the primary outcome measure being used to establish the performance (efficacy and safety) of a new drug

1756. Newer Medications for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/prostatic-hyperplasia-medications_research-protocol.pdf
      April 21, 2015 - In the early 1990s, the Federal Drug Administration (FDA) approval of medications for BPH shifted LUTS … prostates with either agent are supported by systematic reviews.10, 13 Recently, newer drugs and other drug … Common medications used to treat LUTS associated with BPH Drug class - Mechanism of action Medication … , drug manufacturer, device trade name, keyword] 109. exp Product Surveillance, Postmarketing/ 110 … . exp "Drug-Related Side Effects and Adverse Reactions"/ 111. exp Adverse Drug Reaction Reporting Systems

1757. Diagnosis and Management of Gout: Current State of the Evidence (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/gout_clinician.pdf
      January 01, 2017 - overall adverse events ��� Subgroup of 1 RCT 2269 Age and race do not affect the efficacy of either drug … include toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), bone marrow suppression, and drug

1758. #06 Developmental Delays ADHD, and Autism (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/06_devdelays_autism_potential_high_impact_june_2012.pdf
      January 01, 2012 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug

1759. Psoriasis-Chronic Executive (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_executive.pdf
      November 01, 2012 - etanercept, and adalimumab), and one anti-IL 12/23 agent (ustekinumab) have approval from the Food and Drug … agents concluded a difference in efficacy, suggesting heterogeneity within the class and indicating drug … and therefore do not make between-class comparisons, rather limit comparisons with the individual drug … systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug … systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug

1760. Evidence Report on the (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/antidepressants-update_research-protocol.pdf
      July 13, 2011 - , continuation phase) or recurrence (i.e., maintenance phase) when a patient 1) continues the drug … medications with new formulations (such as an extended release formulation) are approved by the Food and Drug … Administration (FDA) through an application called a supplemental new drug application (sNDA). … interest is whether response or remission can be maintained if patients who have responded to one drug … If fewer than three head-to-head trials are available for any drug comparison, we will compute indirect